Abbott Laboratories (NYSE:ABT) is a business that is not showcasing any rapid growth trends. However, what makes it an attractive investment prospect is the company’s consistent track record of incremental dividends, with 411 consecutive quarterly payouts since 1924. Along with the company’s underlying business mix, it makes Abbott a suitable investment for dividend hunters. The stock closed at $97.50 on October 2, stretching its bearish run during 2026.
It is down 22.18% on year-to-date basis, and has lagged the broader S&P 500 index by around 42 percentage points over the last 52 weeks. As a dividend healthcare stock, explore how Abbott compares with Gilead, as both companies have different underlying strategies to back their payouts.
Is Abbott’s Reported Growth as Strong as It Looks?
Abbott posted$12.59 billion in second-quarter 2026 revenue, up 13% on a reported basis, although comparable sales growth was a more modest 4.8% as the Exact Sciences acquisition boosted reported growth. The company’s medical devices segment accounted for more than 46% of the topline. Its adjusted earnings grew 4% to $1.31 per share for the quarter. It has delivered $46.58 billion in revenues over the trailing twelve-month period.
The profitability margins are sound but not extraordinary. On a trailing basis, Abbott has generated 14.71% operating margin and 11.65% profit margin. Given the scale of the business, the figures appear very reasonable, which makes it hard to justify the stock’s dip.
Diversified Healthcare Giant Trading at a Discount
Abbott’s diverse portfolio of offerings spans across several areas including diagnostics, medical devices, nutrition and pharmaceuticals. The company’s new cancer diagnostics segment, following its $21 billion acquisition of Exact Sciences earlier this year, carries the potential to add around $3 billion to its annual sales. This would take Abbott’s overall diagnostics revenue scale beyond the $12 billion mark. That defensive profile also helped Abbott earn a spot on our latest list of 10 Best Bear Market Stocks to Invest In Right Now.
As of the latest quarter, the company carried a total debt balance of $32.72 billion which equates to a debt-to-equity ratio above 63%. This is a significant amount of financial leverage, but the risk gets offset by robust cash flow generation capacity. Abbott has generated $9.91 billion in operating cash flows during the trailing twelve months, and its levered free cash flows stood at $7.21 billion. This gives the management enough room to continue its payouts and also invest in additional growth avenues. With an extensive track record of dividends, Abbott’s risk-reward analysis becomes even more important for investors. Lets compare it with another healthcare giant, Pfizer.
Institutional Sentiment
Based on data tracked across 1,000+ hedge funds by Insider Monkey, institutional sentiment toward the company remains strong. According to 13F filing data, number of smart-money managers with long-term exposure in the stock has been going up. A total of 86 hedge funds held positions by the end of Q2 2026, compared to 73 in Q1 2026.
BlackRock is the largest institutional stakeholder, as per Yahoo Finance database, holding 152.56 million shares as of June 30. This amounts to 8.82% of outstanding shares. Other notable institutional investors include Vanguard Capital Management and State Street Corporation, holding 6.57% and 4.68% of outstanding shares respectively.
Conclusion
At its October 2 closing price of $97.50, Abbott had a market capitalization of roughly $169 billion and traded at a relatively high trailing earnings multiple. However, the forward P/E metric of 17.09x indicates expectations of earnings to jump sharply. This makes the current price range look more reasonable, but a lot depends on how the growth outlook materializes. Short interest in the stock remains low. Abbott’s 1.29% short float shows that not too many bearish traders are piling in. It has a short ratio of 2.48 which reflects on very nominal risk of liquidity squeeze. Overall, Abbott looks more reasonably valued after its 2026 selloff, but it is not an obvious bargain unless earnings growth accelerates enough to justify the current multiple.
READ NEXT: Nordson’s (NDSN) New Vantage XL Addresses Increasing Advanced Semiconductor Packaging Demand and Semtech’s (SMTC) LoRa Plus Expansion Is Bigger Than Two New Chips.
